Jetcraft First to Offer Microshield 360 Antimicrobial Treatment by F/LIST
20.7.2020 11:00:00 EEST | Business Wire | Press release
Jetcraft, the world leader in business jet sales and acquisitions, is the launch customer for interiors specialist F/LIST’s Microshield 360 treatment program, which protects against SARS-CoV-2* and other pathogens that may otherwise live on cabin surfaces.
Additionally, Jetcraft is the first aircraft dealer using MicroShield 360. The coating system is available for all in-service aircraft purchased through the company, and will be applied to all eligible aircraft within Jetcraft’s owned inventory, beginning July 14.
Chad Anderson, president at Jetcraft, says: “MicroShield 360 is one of many ways we are expanding our offering to meet clients’ needs during Covid-19. We are pleased to be the first aircraft dealer implementing the treatment, so buyers can be confident their health is protected when purchasing directly from Jetcraft.
“Our first two jets, a Bombardier Challenger 604 and Global 5000, were treated by F/LIST on July 14. I was highly impressed by the speed of the application, which only took two hours from start to finish for a whole year of protection.”
MicroShield 360 is an antimicrobial coating system which is colorless, odorless and safe for all aircraft interiors. Owners can be reassured that it is eco-friendly, non-toxic and hypoallergenic, and won’t cause any deterioration to their aircraft cabin.
The interior application takes place in two parts: an initial disinfectant to sterilize the cabin, followed by the application of MicroShield 360, which forms a barrier of nanoscopic spikes. The spikes physically destroy germs by piercing the cell membranes, preventing them from adhering to and contaminating a surface.
An electrostatic sprayer is used to apply MicroShield 360, generating a molecular bond with the cabin surface which is equal to 40x the pull of gravity. As a result, the system is extremely abrasion resistant. Combined with regular cleaning, the treatment will ensure all surfaces are effectively self-disinfecting for 12+ months.
Sean Johnson, CEO, F/LIST Canada, adds: “In the present climate, it pays to be fastidious about your health and the cleanliness of your environment, particularly whilst traveling. With F/List partnering with Jetcraft we can bring MicroShield 360 directly to new aircraft owners, underlining how safe, controlled and comfortable travel can be when flying privately. F/List has long been known for innovative technologies that upgrade the cabin experience, and MicroShield 360 falls perfectly into that category.”
All Microshield 360 treatments are subject to Jetcraft approval. Some exclusions apply.
*SARS-CoV-2 is the virus that causes Covid-19.
ENDS
About Jetcraft
Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.
For more information, please visit www.jetcraft.com
About F/LIST
F/LIST is a worldwide provider of interiors for business jets, yachts and residences, and engages more than 900 employees at eight locations in Europe, the Middle East and the Americas. Passion, reliability and a visionary spirit determine every step of this Austrian family-run business.
For more information, please visit https://f-list.at/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005038/en/
Contact information
8020 Communications.
Michaela Wilkins
Email: jetcraft@8020comms.com
Telephone: +44 (0)1483 447380
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom